Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Albuterol Sulfate HFA in Mild Asthma
NCT06618105Phase 3Not yet recruiting
- Sponsor
- Macleods Pharmaceuticals Limited
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of salbutamol in asthma (4 arms), sponsored by Macleods Pharmaceuticals Limited. Primary endpoint: Post-dose PC20. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
salbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06618105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618105.